KURA
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
Follow Play Earnings CallPlay Earnings Call Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML December 8, 2025 12:30 PM EST Company Participants Troy Wilson – Chairman, CEO & PresidentMollie Leoni – Chief Medical Officer Conference Call Participants Amer ZeidanEunice WangLi Wang Watsek – Cantor Fitzgerald & […]
Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology – Slideshow
Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology – Slideshow
Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript
Follow Play Earnings CallPlay Earnings Call Kura Oncology, Inc. (NASDAQ:KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology October 18, 2025 1:30 PM EDT Company Participants Troy Wilson – Chairman, CEO & PresidentMollie Leoni – Chief Medical Officer Conference Call Participants Glenn J. HannaJonathan Chang – Leerink Partners LLC, Research […]